Physician profile

Robert A Hanson

Cardiovascular Disease · Chandler, AZ

NPI 1932328978

$8,786.99

in general payments reported to CMS, 2019-2025

40 companies · $2,315 in 2025

The $2,315 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,567.04
Education$20.22

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Heartflow, INC. $1,592.63 2023-2025 Ffrct
Abbott Laboratories $940.27 2019-2025 Cardiomems, Mitraclip, Gallant
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $893.75 2019-2025 Lifevest
Boston Scientific Corporation $749.97 2020-2025 Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Watchman Flx
Aop Health US, LLC $538.39 2025 Rapiblyk
Novartis Pharmaceuticals Corporation $477.06 2019-2025
Janssen Pharmaceuticals, INC $441.04 2019-2024 Xarelto
Medtronic, INC. $376.46 2021-2025 Venaseal, Corevalve Evolut R
E.R. Squibb & Sons, L.L.C. $304.01 2022-2025 Camzyos, Eliquis
Atricure, INC. $291.97 2022-2024
Esperion Therapeutics, INC. $231.88 2021-2022
Pfizer INC. $195.90 2020-2025
Merck Sharp & Dohme LLC $176.10 2021-2024 Verquvo
Baxter Healthcare $153.86 2023-2025 Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor
Sanofi-Aventis U.S. LLC $152.18 2019-2023
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $141.89 2019-2025 Repatha, Repatha
Bardy Diagnostics, INC. $110.00 2019-2022
Kestra Medical Technology Services, INC. $89.68 2025 Assure Wcd
Edwards Lifesciences Corporation $88.59 2020-2025 Sapien 3 Ultra Resilia
Medtronic Vascular, INC. $88.01 2019
Amarin Pharma, INC. $85.60 2019-2021
Astrazeneca Pharmaceuticals Lp $76.88 2020-2024
Tactile Systems Technology INC $64.78 2020-2024 Flexitouch Plus, Entre Plus
Kowa Pharmaceuticals America, INC. $58.15 2019-2021
Astellas Pharma US INC $50.12 2021-2022
Novo Nordisk INC $39.75 2025 Wegovy
Biocompatibles, INC. $39.37 2019
Cvrx, INC. $38.19 2024 Barostim Neo System
Bayer Healthcare Pharmaceuticals INC. $36.77 2025
Ge Healthcare $35.06 2023
Regeneron Healthcare Solutions, INC. $34.17 2019
Impulse Dynamics (USA) INC. $32.18 2022
Alnylam Pharmaceuticals INC. $29.33 2022-2024 Amvuttra
Actelion Pharmaceuticals US, INC. $26.89 2022
Kiniksa Pharmaceuticals International, Plc $21.69 2024 Arcalyst
Lexicon Pharmaceuticals, INC. $19.93 2024
Inspire Medical Systems, INC. $18.77 2025 Inspire
Arbor Pharmaceuticals, INC. $16.40 2020
Acacia Pharma INC $15.11 2022
Boehringer Ingelheim Pharmaceuticals, INC. $14.21 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert A Hanson

$8,786.99

in general payments reported 2019-2025

Years
2019-2025
Top company
Heartflow, INC.
Context
The $2,315 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/360701/robert-a-hanson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.